Reactivation of latent granulomatous infections by infliximab

Clinical Infectious Diseases

Volumn 41, Issue 3 SUPPL., 2005, Pages

  Wallis, Robert S ^a,e,f   Broder, Michael ^b   Wong, John ^c   Lee, Albert ^d   Hoq, Lalima ^d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^c Buck Consulting   (United States)

^d Cerner Health Insights   (United States)

^e PPD   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; PREDNISONE;

ASPERGILLOSIS; CANDIDIASIS; COCCIDIOIDOMYCOSIS; CROHN DISEASE; CRYPTOCOCCOSIS; DISEASE EXACERBATION; DRUG ACTIVITY; GRANULOMATOUS INFLAMMATION; HISTOPLASMOSIS; HUMAN; LEGIONNAIRE DISEASE; LEPROSY; LISTERIOSIS; NOCARDIOSIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REVIEW; SALMONELLOSIS; TOXOPLASMOSIS; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; APOPTOSIS; GRANULOMA; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22544436130     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429996     Document Type: Review

References (31)

1. Rich EA, Torres M, Sada E, Finegan CK, Hamilton BD, Toossi Z. Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuber Lung Dis 1997; 78:247-55.
2. Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ inimunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153-5.
3. Karakousis PC, Yoshimatsu T, Lamichhane G, et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 2004; 200:647-57.
4. Wallis RS, Amir-Tahmasseb M, Ellner JJ. Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte Western blot. Proc Natl Acad Sci USA 1990; 87:3348-52.
5. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
6. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168:4620-7.
7. Kindler V, Sappino AP. The beneficial effects of localized tumor necrosis factor production in BCG infection. Behring Inst Mitt 1991; 88:120-4.
8. 500,000 patients have now been treated with REMICADE® worldwide. Pharmaceutical News, 21 April 2004. Available at: http://www.news -medical.net/?id = 729. Accessed 11 May 2005.
9. FDA approves new and easy way to take Enbrel [press release]. Thousand Oaks, CA: Amgen, 2004. Available at: http://www.enbrel.com/ news/pdf/ Enbrel_50mg_Approval.pdf. Accessed 23 March 2005.
10. Wallis RS, Broder MS, Wong JY, Hanson JY, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5.
11. Wallis RS, Broder MS, Wong JY, Beenhouwer DO. Granulomatous infections due to tumor necrosis factor blockade [correction]. Clin Infect Dis 2004; 39:1254-6.
12. Daniel TM, Debanne SM. Estimation of the annual risk of tuberculosis infection for white men in the United States. J Infect Dis 1997; 175: 1535-7.
13. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2000. Atlanta: US Department of Health and Human Services, 2001. Available at: http://www.cdc.gov/nchstp/tb/surv/surv2000 /default.htm. Accessed 23 March 2005.
14. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with TNF antagonists. Arthritis Rheum 2004; 50:1959-66.
15. Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003; 37:577-81.
16. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:1303-7.
17. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177-85.
18. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-94.
19. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:22-8.
20. van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-85.
21. di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53:70-7.
22. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001; 410:101-5.
23. Mackay CR, Marston WL, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med 1990; 171: 801-17.
24. Oliveira Pinto LM, Garcia S, Lecoeur H, Rapp C, Gougeon ML. Increased sensitivity of T lymphocytes to tumor necrosis factor receptor 1 (TNFR1)- and TNFR2-mediated apoptosis in HIV infection: relation to expression of Bcl-2 and active caspase-8 and caspase-3. Blood 2002; 99:1666-75.
25. + T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002; 8:319-23.
26. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129-35.
27. Hirsch CS, Toossi Z, Othieno C, et al. Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 1999; 180:2069-73.
28. Wallis RS, Helfand MS, Whalen C, et al. Immune activation, allergic drug toxicity, and mortality in HIV-positive tuberculosis. Tuber Lung Dis 1996; 77:516-23.
29. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257-64.
30. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995; 171:523-30.
31. 3. J Acquir Immune Defic Syndr 2003; 32:281-6.